



Stockholm, 2020-02-06

PRESS RELEASE

Successful development of analysis methods for QPG-1029

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, today announces that the company, in collaboration with a reputable global contract research company, has developed bioanalytical methods for the drug candidate QPG-1029 (PEG liraglutide) and the active drug substance liraglutide.

Bioanalytical methods are used to determine drug concentration in biological fluids, such as blood plasma. This is necessary for evaluation of how a drug circulates in the body.

"This is an important milestone for our continued development program and enables a detailed analysis of QPG-1029. Results from a pharmacokinetic study and efficacy data from a so-called proof-of-principle study, will be presented in the near future. ", says QuiaPEG's CEO Marcus Bosson.

QPG-1029 is an improved version of the existing drug liraglutide, for the treatment of diabetes and obesity. Before the latter parts of the preclinical program and the first clinical trial is initiated, the methods of analysis will undergo a more extensive evaluation in the form of a validation process where additional parameters are analyzed to verify the reliability of the methods.

For further information contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53

E-mail: marcus.bosson@quiapeg.com www.quiapeg.com

This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to provide to publish according to the Act (1991: 980) on trading in financial instruments. The information was provided, through the contact person above, for publication on February 6, 2020.

About QuiaPEG Pharmaceuticals

QuiaPEG Pharmaceuticals Holding AB conducts research and development activities and commercialization of pharmaceuticals based on the company's unique patent pending technology platform, Uni-Qleaver®. The company develops improved and patentable forms of drugs that are under development or that have already been approved by pharmaceutical authorities. These refined and improved forms of medicines are based on Uni-Qleaver®. The company's share has been listed on Spotlight Stock Market since March 29, 2017.